Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Transgenic mice expressing human neonatal Fc receptor (FcRn) instead of mouse FcRn are available for IgG antibody pharmacokinetic (PK) studies. Given the interest in a rodent model that offers reliable predictions of antibody PK in monkeys and humans, we set out to test whether the PK of IgG antibodies in such mice correlated with the PK of the same antibodies in primates. We began by using a single research antibody to study the influence of: (1) different transgenic mouse lines that differ in FcRn transgene expression; (2) homozygous vs. hemizygous FcRn transgenic mice; (3) the presence vs. absence of coinjected high-dose human intravenous immunoglobulin (IVIG), and (4) the presence vs. absence of coinjected high-dose human serum albumin (HSA). Results of those studies suggested that use of hemizygous Tg32 mice (Tg32 hemi) not treated with IVIG or HSA offered potential as a predictive model for PK in humans. Mouse PK studies were then done under those conditions with a panel of test antibodies whose PK in mice and primates is not significantly affected by target binding, and for which monkey or human PK data were readily available. Results from the studies revealed significant correlations between terminal half-life or clearance values observed in the mice and the corresponding values reported in humans. A significant relationship in clearance values between mice and monkeys was also observed. These correlations suggest that the Tg32 hemi mouse model, which is both convenient and cost-effective, can offer value in predicting antibody half-life and clearance in primates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346 · cited 2×
“Therefore, low levels of endogenous IgG are predicted in these mice.(4,8,9) To confirm that the untreated transgenic mice we used had low levels of endogenous IgG compared with normal mice, IgG serum levels were measured with a mouse IgGspecific ELISA.”
BackgroundClinical Pharmacokinetics of Therapeutic Monoclonal Antibodies
Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M., & Beijnen, J. H. (2010) · Clinical Pharmacokinetics · doi:10.2165/11531280-000000000-00000 · Cited by 725
Chaudhury, C., Mehnaz, S., Robinson, J. M., Hayton, W. L., Pearl, D. K., Roopenian, D. C., & Anderson, C. L. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021829 · Cited by 640
Albumin Binding to FcRn: Distinct from the FcRn−IgG Interaction
Chaudhury, C., Brooks, C. L., Carter, D. C., Robinson, J. M., & Anderson, C. L. (2006) · Biochemistry · doi:10.1021/bi052628y · Cited by 290 · cited 1×
“bind to distinct sites on FcRn, and that IgG bound to FcRn does not affect binding of that same FcRn to albumin, definitive data on whether albumin affects IgG binding to FcRn may still be lacking.(11) The endogenous levels of serum albumin in untreated normal and FcRn-related mouse lines were measured by a mouse seru…”
MethodAn Engineered Human IgG1 Antibody with Longer Serum Half-Life
Hinton, P. R., Xiong, J. M., Johlfs, M. G., Tang, M. T., Keller, S., & Tsurushita, N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.346 · Cited by 282
Interspecies Scaling of Therapeutic Monoclonal Antibodies: Initial Look
Ling, J., Zhou, H., Jiao, Q., & Davis, H. M. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009337134 · Cited by 144 · cited 3×
“An additional comparison was made between monkey antibody PK values from internal or published data, and the data from J&J clinical trials.(12,13) For 9 antibodies for which human PK data were available, the correlation tests showed that the relationship between monkey clearance and human clearance was significant (Fi…”
BackgroundResult
Cited by
Distribution of FcRn Across Species and Tissues
Latvala, S., Jacobsen, B., Otteneder, M. B., Herrmann, A., & Kronenberg, S. (2017) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155417705095 · Cited by 178
“Various PK profiles of IgG have been observed,(23) raising the question about selection of the best model for PK prediction in humans.(30,31) Recent attempts have been made to quantify the amount of FcRn protein levels in tissue of transgenic mice.”
BackgroundFc Sialylation Prolongs Serum Half-Life of Therapeutic Antibodies
Bas, M., Terrier, A., Jacque, E., Dehenne, A., Pochet-Béghin, V., Beghin, C., Dezetter, A.-S., Dupont, G., Engrand, A., Beaufils, B., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800896 · Cited by 82
Direct Pro-Inflammatory Effects of Prorenin on Microglia
Shi, P., Grobe, J. L., Desland, F. A., Zhou, G., Shen, X. Z., Shan, Z., Liu, M., Raizada, M. K., & Sumners, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092937 · Cited by 75
Wang, J., Iyer, S., Fielder, P. J., Davis, J. D., & Deng, R. (2016) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1952 · Cited by 69
Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates
Dostalek, M., Prueksaritanont, T., & Kelley, R. F. (2017) · mAbs · doi:10.1080/19420862.2017.1323160 · Cited by 45
“A significant relationship in clearance and elimination half-life values between the transgenic FcRn mouse models and cynomolgus monkey was observed for a panel of monoclonal antibodies whose target binding does not affect their clearance in either mouse or cynomolgus monkey.(62) The authors demonstrated similar elimi…”
BackgroundRichter, W. F., Christianson, G. J., Frances, N., Grimm, H. P., Proetzel, G., & Roopenian, D. C. (2018) · mAbs · doi:10.1080/19420862.2018.1458808 · Cited by 39
Metadata
- Authors
- Tam, S. H., McCarthy, S. G., Brosnan, K., Goldberg, K. M., & Scallon, B. J.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2013-05
- Volume
- 5
- Issue
- 3
- Pages
- 397-405
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W1983274526
- Cited by
- 69
- References
- 6
- FWCI
- 5.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.